Cellular Biomedicine (PRIVATE.CBMG)

Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers. It also uses human adipose-derived mesenchymal progenitor cells for the treatment of joint disease. Additionally, the company develops human umbilical cord-derived mesenchymal progenitor cells and human embryo-derived motor neuron progenitor precursor cells. Finally, it creates human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases. In addition to its therapeutic initiatives, the company provides consulting services to businesses seeking access to the U.S. capital markets. The company is headquartered in Palo Alto, California.